By Fineline Cube Everest Medicines (HKG: 1952) announced a strategic licensing agreement with domestic peer Corxel Pharmaceuticals Limited (CORXEL) for LNZ100, a once-daily prescription eye drop indicated for the treatment of presbyopia. Under the terms, Everest will make an undisclosed upfront payment, milestone payments, and annual net sales-based tiered royalties in exchange for exclusive development, manufacturing, and commercialization rights across Greater China.
Deal Structure & Territory Rights
| Item | Detail |
|---|---|
| Licenser | Corxel Pharmaceuticals Limited (CORXEL) |
| Licensee | Everest Medicines (HKG: 1952) |
| Asset | LNZ100 (aceclidine ophthalmic solution) |
| Indication | Treatment of presbyopia (age-related near vision loss) |
| Territory | Greater China (Mainland China, Hong Kong, Macau, Taiwan) |
| Payment Structure | Upfront + milestones + tiered royalties on net sales |
| Rights Granted | Full development, manufacturing, and commercialization |
Drug Profile & Mechanism of Action
- Active Ingredient: Aceclidine – small-molecule muscarinic acetylcholine receptor agonist
- Dosage Form: Once-daily prescription eye drop
- Primary Mechanism: Induces pupillary constriction (miosis) creating a pinhole effect that improves near vision
- Key Innovation: Decouples miosis from myopic shift – produces therapeutic miotic effect while avoiding common side effect of blurred distance vision
- Patient Population: Broad applicability across presbyopia patients due to selective pupillary mechanism
Development History & Regulatory Status
| Milestone | Date | Entity |
|---|---|---|
| Original Developer | – | LENZ Therapeutics (Nasdaq: LENZ) |
| US FDA Approval | July 2025 | LENZ Therapeutics |
| Corxel Licensing | April 2022 | CORXEL secured development/commercialization rights |
| Greater China Licensing | June 2026 | Everest Medicines |
Market Opportunity & Strategic Rationale
- Presbyopia Prevalence: Affects over 1.8 billion people globally, with significant unmet need in aging Greater China population
- Competitive Landscape: Limited pharmacological options; most patients rely on reading glasses or surgical interventions
- Everest’s Position: Strengthens company’s ophthalmology portfolio with innovative mechanism-of-action asset
- Commercial Infrastructure: Everest’s established presence in Greater China provides immediate market access upon regulatory approval
- Revenue Potential: Presbyopia market projected to reach $5.2 billion globally by 2030, with Asia-Pacific representing fastest-growing segment
Forward‑Looking Statements
This brief contains forward-looking statements regarding licensing arrangements, regulatory pathways, and commercial expectations for LNZ100. Actual results may differ due to risks including regulatory approval timelines, market adoption, competitive dynamics, and clinical performance in real-world settings.-Fineline Info & Tech